FR2622113A1 - Medicament comprising a combination of polymyxin B, amikacin and amphotericin B administered by vaporisation - Google Patents
Medicament comprising a combination of polymyxin B, amikacin and amphotericin B administered by vaporisation Download PDFInfo
- Publication number
- FR2622113A1 FR2622113A1 FR8714790A FR8714790A FR2622113A1 FR 2622113 A1 FR2622113 A1 FR 2622113A1 FR 8714790 A FR8714790 A FR 8714790A FR 8714790 A FR8714790 A FR 8714790A FR 2622113 A1 FR2622113 A1 FR 2622113A1
- Authority
- FR
- France
- Prior art keywords
- vaporisation
- administered
- polymyxin
- amikacin
- nasal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
La présente invention concerne un médicament pour vaporisation destiné à prévenir les risques d'infection chez les malades à risques en décontaminant les cavités nasales et oropharyngées
Les infections à bacilles gram négatif et les mycoses sont fréquentes chez les malades à risques . Elles entraînent une morbidité importante , elles sont une des causes principales du décès de ces patients , elles augmentent les dépenses de santé en augmentant les durées d'hospitalisation
La présente invention permet de remédier à cet inconvénient . Elle comporte l'association de trois antibiotiques administrée par vaporisation dans les cavités nasales et orophryngées . Les trois antibiotiques associés dans la préparation sont la polymyxine B , 1'amikacine et l'amphotéricine B .La préparation doit adhérer aux muqueuses nasales et buccales , relarguer lentement les antibiotiques et avoir une tension superficielle permettant un étalement maximal sur les muqueuses nasales et oropharyngées . La préparation est administrée par vaporisation précise soit sous forme d'aérosol pressurisé distribué par une valve continue ou doseuse soit sous forme de nébulisation distribuée par une pompe précise .Deux poussoirs sont fournis avec chaque flacon : l'un disposant d'une canule longue et fine permettant l'introduction par les narines et la vaporisation des fosses nasales , l'autre d'une canule permettant une vaporisation large de la cavité oropharyngée
Les doses distribuées par les valves ou les pompes seront très précises
Elles sont bien entendu fonction de la concentration des antibiotiques au sein de la préparation
La fréquence des applications dépend également de la concentration de ces produits.The present invention relates to a spray medication intended to prevent the risks of infection in patients at risk by decontaminating the nasal and oropharyngeal cavities.
Gram-negative bacillus infections and yeast infections are common in at-risk patients. They cause significant morbidity, they are one of the main causes of the death of these patients, they increase healthcare costs by increasing hospital stays
The present invention overcomes this drawback. It involves the combination of three antibiotics administered by spraying into the nasal and orophryngeal cavities. The three antibiotics associated in the preparation are polymyxin B, amikacin and amphotericin B. The preparation must adhere to the nasal and oral mucous membranes, slowly release the antibiotics and have a surface tension allowing maximum spreading on the nasal and oropharyngeal mucous membranes . The preparation is administered by precise spraying either in the form of a pressurized aerosol distributed by a continuous or metering valve or in the form of nebulization distributed by a precise pump. Two pushers are supplied with each bottle: one having a long cannula and fine allowing the introduction through the nostrils and vaporization of the nasal cavities, the other of a cannula allowing a broad vaporization of the oropharyngeal cavity
The doses distributed by the valves or the pumps will be very precise
They are of course a function of the concentration of antibiotics within the preparation
The frequency of applications also depends on the concentration of these products.
Aucun de ces antibiotiques n'étant absorbé par voie nasale , oropharyngée ou digestive , les posologies et donc les concentrations peuvent varier dans une très large part
Les caractéristiques et avantages de l'invention ressortent de la description qui va suivre à titre d'exemple : pour 30 ml de préparation , on associe
-sulfate de polymyxine B : 500 mg
-sulfate d'amikacine :1250 mg
-amphotéricine B : 2500 mg
-alcool à 90 : 1 ml
-saccharinate de sodium : 100 mg
-essence de menthe : 0,02ml
-glycérine : quantité suffisante
pour 30 ml
La valve ou la pompe doit être adaptée pour délivrer 0,5 ml à chaque pression . On recommande 6 pressions dans la cavité oropharyngée , 3 pressions dans chaque narine à chaque administration et une fréquence de quatre administrations par jour . Dans cet exemple , on administre 400 mg de polymyxine
B , 1000 mg d'amikacine et 2000 mg d' amphotéricine B par jour
Ilest recommandé d'associer la vaporisation nasale et oropharyngée à une décontamination sélective du tube digestif par administration orale ou par sonde gastrique avec ces même antibiotiques . None of these antibiotics being absorbed via the nasal, oropharyngeal or digestive route, the dosages and therefore the concentrations can vary to a very large extent.
The characteristics and advantages of the invention appear from the description which follows by way of example: for 30 ml of preparation, one associates
-polymyxin B sulfate: 500 mg
-amikacin sulfate: 1250 mg
-amphotericin B: 2500 mg
- 90 alcohol: 1 ml
-sodium saccharinate: 100 mg
-mint essence: 0.02ml
-glycerin: sufficient amount
for 30 ml
The valve or pump must be adapted to deliver 0.5 ml each time it is pressed. We recommend 6 pressures in the oropharyngeal cavity, 3 pressures in each nostril with each administration and a frequency of four administrations per day. In this example, 400 mg of polymyxin is administered
B, 1000 mg of amikacin and 2000 mg of amphotericin B per day
It is recommended to combine nasal and oropharyngeal spraying with selective decontamination of the digestive tract by oral administration or by gastric tube with these same antibiotics.
Les indications de ce médicament sont très larges : ildoit être employé chaque fois qu'un risque d'infection à gram négatif ou de mycose est présent: en réanimation , en hématologie , en chirurgie ,en anesthésiologie , en cancérologie , etc... The indications for this drug are very broad: it must be used whenever a risk of gram negative infection or mycosis is present: in intensive care, hematology, surgery, anesthesiology, oncology, etc ...
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8714790A FR2622113A1 (en) | 1987-10-27 | 1987-10-27 | Medicament comprising a combination of polymyxin B, amikacin and amphotericin B administered by vaporisation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8714790A FR2622113A1 (en) | 1987-10-27 | 1987-10-27 | Medicament comprising a combination of polymyxin B, amikacin and amphotericin B administered by vaporisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR2622113A1 true FR2622113A1 (en) | 1989-04-28 |
Family
ID=9356169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8714790A Withdrawn FR2622113A1 (en) | 1987-10-27 | 1987-10-27 | Medicament comprising a combination of polymyxin B, amikacin and amphotericin B administered by vaporisation |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2622113A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7971588B2 (en) * | 2000-05-05 | 2011-07-05 | Novartis Ag | Methods and systems for operating an aerosol generator |
| US8336545B2 (en) | 2000-05-05 | 2012-12-25 | Novartis Pharma Ag | Methods and systems for operating an aerosol generator |
-
1987
- 1987-10-27 FR FR8714790A patent/FR2622113A1/en not_active Withdrawn
Non-Patent Citations (4)
| Title |
|---|
| BIOLOGICAL ABSTRACTS no. 30100848, Tsai W. et al: Campylobacter enteritis in children & Acta Pediatrica sinica, 1985, vol. 26, no. 5, pages 436 - 422 * |
| CHEMICAL ABSTRACTS, vol. 80, no. 13, 1 avril 1974, page 6; colonne 1; ref. no. 66606k, KUWANO M. et al: 'Synergistic effect of fusidic acid with polymyxin B and amphoterican B on transformed and normal fibroblastic cells' Gann, 1973, 64(4), pages 337 - 343 * |
| CHEMICAL ABSTRACTS, vol. 83, no.23, 8 décembre 1975, page 77; colonne 2; ref. no. 188769y, COLLINS M. et al: 'Inhibitions of Coccidoides iimmitis in vitro and enhacement of anticoccidiodal effects of amphotericin B by polymyxin B' & Antimicrob Agents Chemother, 1975, 7(6), pages 781 - 787 * |
| CHEMICAL ABSTRACTS, vol. 98, no. 18, 2 mai 1983, page 260, colonne 2; ref. no. 157786g, MIYANO N. et al. 'Interaction on the in vitro antimicrobial activity between amphotericin Band polymyxin B' & Yaruzaigaru, 1982, 42(4), pages 357 - 360 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7971588B2 (en) * | 2000-05-05 | 2011-07-05 | Novartis Ag | Methods and systems for operating an aerosol generator |
| US8336545B2 (en) | 2000-05-05 | 2012-12-25 | Novartis Pharma Ag | Methods and systems for operating an aerosol generator |
| US8196573B2 (en) | 2001-03-20 | 2012-06-12 | Novartis Ag | Methods and systems for operating an aerosol generator |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2621817A1 (en) | DRUG COMPRISING POLYMYXIN B, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED | |
| FR2624015A1 (en) | MEDICINE COMPRISING THE COMBINATION OF COLISTINE, TOBRAMYCIN AND AMPHOTERICIN B VAPORIZED | |
| FR2621818A1 (en) | MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION | |
| ES2330415T3 (en) | SYSTEM FOR OSMOTIC SUPPLY OF PHARMACEUTICAL ACTIVE AGENTS. | |
| CA2039456A1 (en) | Osmotic dosage system for liquid drug delivery | |
| ATE392885T1 (en) | ADMINISTRATION SYSTEMS FOR ORAL MEDICATIONS | |
| ES2104522T3 (en) | NEW MEDICINAL ADMINISTRATION SYSTEM. | |
| KR880002502A (en) | Formulations for Administration of Beneficial Acid Sensitive Agents | |
| KR880013586A (en) | Dosage device comprising a removable substrate with a solid state property | |
| ATE261301T1 (en) | MEDICINAL PREPARATIONS CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | |
| DK0998916T3 (en) | Medicines for administration to the mucosa | |
| ATE138071T1 (en) | LIPID AIDS FOR ADMINISTRATION THROUGH THE NOSE AND TOPICAL APPLICATION | |
| DE69001812T2 (en) | SYSTEM FOR PARENTERAL ADMINISTRATION OF AN ACTIVE SUBSTANCE. | |
| US4876283A (en) | Antisnoring agent | |
| EP0207041A3 (en) | Pharmaceutical tablets for easy administration of pellets, their preparation and use | |
| CA1223210A (en) | Antisnoring agent | |
| CA2433833A1 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
| KR970032872A (en) | Drugs for the treatment of skin damage containing acetylsalicylic acid | |
| JPH07506839A (en) | Sprayable analgesic compositions and methods of use thereof | |
| FR2624017A1 (en) | Medicament comprising a combination of colistin, amikacin and amphotericin B administered by vaporisation | |
| FR2622113A1 (en) | Medicament comprising a combination of polymyxin B, amikacin and amphotericin B administered by vaporisation | |
| CA2296231C (en) | Composition and method for treating common viral infections | |
| FR2624738A1 (en) | Medicament comprising a combination of colistin, sissomicin and amphotericin B administered by vaporisation | |
| FR2624739A1 (en) | Medicament comprising a combination of colistin, neomycin and amphotericin B administered by vaporisation | |
| FR2622111A1 (en) | Medicament comprising a combination of polymyxin B, dibekacin and amphotericin B administered by vaporisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |